Perspective Therapeutics provides VMT-α-NET and pipeline updates; 76% progression-free in NET trial

Perspective Therapeutics, Inc.

VMT-α-NET Cohort 2: 19/25 pts (76%) progression-free at median ~13 wks additional follow-up vs ESMO 2025; 9/23 (39%) had RECIST response.
Safety in 56 pts: no DLTs, no treatment-related discontinuations; Grade 3+ AEs in 37.5%, one transient Grade 4 lymphopenia.
Cohort 3 (6.0 mCi) cleared by SMC after 8-patient DLT review; 9 patients treated as of Dec 31, 2025.
VMT01 melanoma: 9 patients dosed at 3.0 mCi (5 with nivolumab, 4 monotherapy) as of Dec 31; data submission planned after 24-week follow-up.
PSV359 FAP-targeting trial: 5 patients dosed across Cohort 1 (2.5 mCi) and Cohort 2 (5.0 mCi) with site activations underway.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.